Study identifies antibiotic resistance in gram-negative uropathogens from diabetic patients, suggesting targeted treatment approaches.
A BSTRACT Aim: This study aimed to identify Gram-negative uropathogens (GN-UP)-producing extended-spectrum beta-lactamases (ESBL), metallo-beta-lactamases (MBL), and AmpC enzymes in diabetic patients and to analyze their antibiotic resistance profiles. Materials and Methods: Urine samples were cultured, and isolates were tested using the Kirby-Bauer disc diffusion method. Results: E. coli (43%) was the most common isolate, followed by Klebsiella spp. (25%). Among GN-UP, 13.26% were ESBL producers, 63.26% MBL producers, and 17.34% AmpC producers. MBL-producing isolates showed lower resistance to fosfomycin (22.58%), tigecycline (32.25%), and nitrofurantoin (33.87%). The high prevalence of MBL, ESBL, and AmpC producers in diabetic urinary tract infection (UTI) patients complicates effective antibiotic therapy. Conclusion: These findings underscore the need for regular antimicrobial surveillance and tailored treatment strategies in this vulnerable group.
No takes yet. Share an insight, caveat, or question.
Patil et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: